Indirect comparison of the short-, mid-, and long-term efficacy of treatments for moderate to severe plaque psoriasis: a systematic review and network meta-analysis

Main Article Content

April W Armstrong
Keck School of Medicine, University of Southern California

Richard B Warren
The University of Manchester

Yichen Zhong
Bristol Myers Squibb

Joe Zhuo
Bristol Myers Squibb

Allie Cichewicz
Evidera

Ananth Kadambi
Evidera

Daniel R Junqueira
Evidera

Tracy Westley
Evidera

Renata Kisa
Bristol Myers Squibb

Carolin Daamen
Bristol Myers Squibb

Matthias Augustin
University Medical Center

Keywords

psoriasis, efficacy, meta-analysis, moderate to severe, deucravacitinib, TYK2 inhibitor

Abstract

N/A

References

1. Guideline on Missing Data in Confirmatory Clinical Trials. European Medicines Agency; 2010. https://www.ema.europa.eu/en/documents/scientifi c-guideline/guideline-missing-data-confi rmatory-clinical-trials_en.pdf

2. Guidance for Sponsors, Clinical Investigators, and IRBs. US Food and Drug Administration; 2008. http://www.fda.gov/downloads/RegulatoryInformation/Guidances/ucm126489.pdf

3. Page MJ, et al. PLoS Med. 2021;18:e1003583.

Article Sidebar

Poster PDF
Published
Nov 16, 2022
DOI https://doi.org/10.25251/skin.6.supp.61

Article Details

How to Cite
Armstrong, A. W., Warren, R. B., Zhong, Y., Zhuo, J., Cichewicz, A., Kadambi, A., Junqueira, D. R., Westley, T., Kisa, R., Daamen, C., & Augustin, M. (2022). Indirect comparison of the short-, mid-, and long-term efficacy of treatments for moderate to severe plaque psoriasis: a systematic review and network meta-analysis. SKIN The Journal of Cutaneous Medicine, 6(6), s61. https://doi.org/10.25251/skin.6.supp.61
Issue
Vol. 6 No. 6 (2022): November Issue & Poster Presentations from FC22 Dermatology Conference®
Section
Poster Presentations from FC22 Dermatology Conference®: Psoriasis
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

<< < 1 2 3 4